Caribou Biosciences, Inc.
- Jurisdiction
United States - ISIN
US1420381089 (CRBU )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Read full profile
Stock price
Fundamentals
- Net revenue
€7.86M - Gross margin
87.0% - EBIT
-€144.40M - EBIT margin
-1,837.6% - Net income
-€141.52M - Net margin
-1,800.9%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts